Arrowhead Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M | $88.0M | $168.8M | $16.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $607.2M | $505.9M | $353.2M | — | — | — | — | — |
| SG&A Expense | $123.9M | $98.8M | $92.5M | $124.4M | $81.0M | $52.3M | $26.6M | $19.1M |
| Operating Income | $98.3M | $-601.1M | $-205.0M | $-178.5M | $-149.0M | $-93.2M | $61.2M | $-55.9M |
| Operating Margin | 11.9% | -16,927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.3% | -346.5% |
| Interest Expense | — | — | $18.3M | $0 | $0 | — | — | — |
| Pretax Income | $51.5M | $-612.5M | $-206.5M | $-172.7M | $-140.8M | $-84.6M | $68.1M | $-54.4M |
| Income Tax Expense | $21.4M | $-2.8M | $2.8M | $3.8M | $2.0K | $2.0K | $174.0K | $2.4K |
| Net Income | $-1.6M | $-599.5M | $-205.3M | $-176.1M | $-140.8M | $-84.6M | $68.0M | $-54.5M |
| Net Margin | -0.2% | -16,882.4% | -85.3% | -72.4% | -101.9% | -96.1% | 40.3% | -337.3% |
| EPS (Basic) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.72 | $-0.65 |
| EPS (Diluted) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.69 | $-0.65 |
| Shares Outstanding (Basic) | 133.8M | 119.8M | 106.8M | 105.4M | 103.7M | 100.7M | 93.9M | 83.6M |
| Shares Outstanding (Diluted) | 133.8M | 119.8M | 106.8M | 105.4M | 103.7M | 100.7M | 98.6M | 83.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |